US approves â¹3 cr cancer drug which uses patient's own cells
US drug regulators have approved a first-of-its-kind customised cancer treatment that uses a patient's own immune cells to fight leukaemia. Priced at $475,000 (over â¹3 crore) by its maker Novartis, the therapy involves custom gene-editing of an individual's T-cells (subtype of white blood cells). FDA gave the approval following a 63-patient study, 83% of whom showed remission within three months.